Page last updated: 2024-12-08
littorine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
littorine: RN given refers to (3(R)-endo)-isomer; RN for cpd without isomeric designation not avail 3/90; isolated from a Duboisia hybrid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Duboisia | genus | A plant genus of the family SOLANACEAE that is a source of SCOPOLAMINE and other TROPANES.[MeSH] | Solanaceae | A plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 443005 |
CHEBI ID | 6506 |
SCHEMBL ID | 24475294 |
MeSH ID | M0174461 |
Synonyms (7)
Synonym |
---|
littorine |
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2r)-2-hydroxy-3-phenylpropanoate |
CHEBI:6506 |
8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-3-phenylpropanoate |
DTXSID20944553 |
Q6653346 |
SCHEMBL24475294 |
Research Excerpts
Overview
Littorine is a key biosynthetic intermediate in the hyoscyamine and scopolamine biosynthesis pathways.
Excerpt | Reference | Relevance |
---|---|---|
"Littorine is a key biosynthetic intermediate in the hyoscyamine and scopolamine biosynthetic pathways." | ( Functional genomics analysis reveals two novel genes required for littorine biosynthesis. Chen, M; Huang, JP; Huang, SX; Kai, G; Lan, X; Liao, Z; Qiu, F; Wang, J; Yang, C; Zeng, J; Zhou, W, 2020) | 1.52 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
tropane alkaloid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathways (4)
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.67) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 9 (60.00) | 29.6817 |
2010's | 2 (13.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 41.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.89) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |